Tacrolimus (MedinCell)

Tier C — Watch / trade

Medincell SA

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：Calcineurin

Indications (approved)：Haematopoietic stem cell transplantation, Myeloproliferative neoplasm, Myelodysplastic syndrome, Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Chronic myelomonocytic leukaemia, Graft-versus-host disease, Haematological malignancy

Regional status

Phase II

2025-03-03

Discontinued

2019-06-07

China

Japan

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Tacrolimus (MedinCell)?

Approved indications include: Haematopoietic stem cell transplantation, Myeloproliferative neoplasm, Myelodysplastic syndrome, Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Chronic myelomonocytic leukaemia, Graft-versus-host disease, Haematological malignancy.

When does the Tacrolimus (MedinCell) patent expire?

No public expiry year is available for Tacrolimus (MedinCell) yet; this page updates once verified.

How do I get a quote for Tacrolimus (MedinCell) intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-01